Literature DB >> 17448576

Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.

Devendra S Puntambekar1, Rajani Giridhar, Mange Ram Yadav.   

Abstract

A three-dimensional quantitative structure-activity relationship (3D-QSAR) study was performed on three different chemical series reported as selective farnesyltransferase (FTase) inhibitors employing comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) techniques to investigate the structural requirements for substrates and derive a predictive model that may be used for the design of novel FTase inhibitors. Removal of outliers improved the predictive power of models developed for all three structurally diverse classes of compounds. 3D-QSAR models were derived for 3-aminopyrrolidinone derivatives (training set N=38, test set N=7), 2-amino-nicotinonitriles (training set N=46, test set N=13) and 1-aryl-1'-imidazolyl methyl ethers (training set N=35, test set N=5). The CoMFA models with steric and electrostatic fields exhibited r(2)(cv) 0.479-0.803, r(2)(ncv) 0.945-0.993, r(2)(pred) 0.686-0.811. The CoMSIA models displayed r(2)(cv) 0.411-0.814, r(2)(ncv) 0.923-0.984, r(2)(pred) 0.399-0.787. 3D contour maps generated from these models were analyzed individually, which provide the regions in space where interactive fields may influence the activity. The superimposition of contour maps on the active site of farnesyltransferase additionally helps in understanding the structural requirements of these inhibitors. 3D-QSAR models developed may guide our efforts in designing and predicting the FTase inhibitory activity of novel molecules.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448576     DOI: 10.1016/j.ejmech.2007.02.003

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors.

Authors:  Hsin-Yuan Wei; Guan-Ju Chen; Chih-Lun Chen; Thy-Hou Lin
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

2.  Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.

Authors:  Mayank Kumar Sharma; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

3.  Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines.

Authors:  Saeed Ghasemi; Soodabeh Davaran; Simin Sharifi; Davoud Asgari; Ali Abdollahi; Javid Shahbazi Mojarrad
Journal:  Adv Pharm Bull       Date:  2013-02-07

4.  Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking.

Authors:  Aihua Xie; Srinivas Odde; Sivaprakasam Prasanna; Robert J Doerksen
Journal:  J Comput Aided Mol Des       Date:  2009-05-29       Impact factor: 3.686

5.  2D-QSAR study of some 2,5-diaminobenzophenone farnesyltransferase inhibitors by different chemometric methods.

Authors:  Saeed Ghanbarzadeh; Saeed Ghasemi; Ali Shayanfar; Heshmatollah Ebrahimi-Najafabadi
Journal:  EXCLI J       Date:  2015-03-30       Impact factor: 4.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.